Copies
to:
|
Daniel
A. Cartwright
Chief
Financial Officer
TherapeuticsMD,
Inc.
6800
Broken Sound Parkway NW, Third Floor
Boca
Raton, Florida 33487
(561)
961-1900
|
Joshua
M. Samek, Esq.
DLA
Piper LLP (US)
200 South Biscayne Boulevard, Suite 2500
Miami, Florida
(305) 423-8500
|
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☒
|
|
Accelerated filer ☐
|
|
Non-accelerated filer ☐
|
|
Smaller reporting company ☐
|
|
|
|
Emerging growth company ☐
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
|
Title of securities to be registered
|
|
Amount to be
registered
(1)
|
|
Proposed maximum
offering price
per share
(3)
|
|
Proposed maximum
aggregate offering
price
|
|
Amount of
registration fee
|
Common Stock, $0.001 par value per share
|
|
|
15,000,000
|
(2)
|
|
$
|
2.54
|
|
|
$
|
38,100,000
|
|
|
$
|
4,617.72
|
|
(1) Pursuant
to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration
Statement on Form S-8 (this “Registration Statement”) also covers an indeterminate number of shares of
common stock, $0.001 par value per share (“Common Stock”), of TherapeuticsMD, Inc. (the “Registrant”)
that may be offered or issued by reason of stock splits, stock dividends or similar transactions effected without the receipt
of consideration which results in an increase in the number of outstanding shares of Common Stock of the Registrant. In
addition, any shares subject to outstanding options or other equity “Awards” (as defined in the TherapeuticsMD,
Inc. 2019 Stock Incentive Plan (the “2019 Plan”)) under the 2019 Plan that are forfeited, expire or otherwise
terminate without issuance of the “Shares” (as defined in the 2019 Plan), or if any Award is settled for cash or
otherwise does not result in the issuance of all or a portion of the Shares subject to such Award (other than Shares tendered
or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the Shares to which
those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance,
again be available for delivery with respect to Awards under the 2019 Plan.
(2)
Shares of Common Stock initially reserved for issuance under the 2019 Plan consist of (i) 15,000,000 shares
registered pursuant to this Registration Statement, plus (ii) 2,392,833 unallocated shares (the “Unused 2012 Plan
Shares”) available for issuance as of June 20, 2019 (the “Effective Date”) under the Registrant’s
Amended & Restated 2012 Stock Incentive Plan (the “2012 Plan”) that are not then subject to outstanding
“Awards” (as defined in the 2012 Plan), plus (iii) 44,300 unallocated shares (the “Unused 2009 Plan
Shares” and, together with the Unused 2012 Plan Shares, the “Unused Plan Shares”) available for issuance as
of the Effective Date under the Registrant’s 2009 Long Term Incentive Compensation Plan, as amended (the “2009
Plan”), that are not then subject to outstanding “Awards” (as defined in the 2009 Plan). Concurrently with
the filing of this Registration Statement, the Registrant is filing a post-effective amendment to its prior registration
statement on Form S-8 (File No. 333-191730), originally filed with the United States Securities and Exchange Commission on
October 15, 2013, to cover the issuance of the Unused Plan Shares under the 2019 Plan. For more details, please see the
explanatory note following this page.
(3)
Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) and (h). The proposed maximum offering
price per share, proposed maximum aggregate offering price and the amount of the registration fee are based on the average of
the high and low prices of Registrant’s Common Stock as reported on The Nasdaq Stock Market LLC on June 17, 2019.
EXPLANATORY
NOTE
This
Registration Statement on Form S-8 (this “Registration Statement”) is filed by TherapeuticsMD, Inc. (the “Registrant”)
to register 15,000,000 shares of common stock, $0.001 par value per share (“Common Stock”), of the Registrant, which
may be issued under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan (the “2019 Plan”).
Shares
of Common Stock initially reserved for issuance under the 2019 Plan consist of (i) 15,000,000 shares of Common Stock
registered pursuant to this Registration Statement, plus (ii) 2,392,833 unallocated shares (the “Unused 2012 Plan
Shares”) available for issuance as of June 20, 2019 (the “Effective Date”) under the Registrant’s
Amended & Restated 2012 Stock Incentive Plan (the “2012 Plan”) that are not then subject to outstanding
“Awards” (as defined in the 2012 Plan), plus (iii) 44,300 unallocated shares (the “Unused 2009 Plan
Shares” and, together with the Unused 2012 Plan Shares, the “Unused Plan Shares”) available for issuance as
of the Effective Date under the Registrant’s 2009 Long Term Incentive Compensation Plan, as amended (the “2009
Plan” and, together with the 2012 Plan, the “Prior Plans” and, collectively with the 2019 Plan, the
“Plans”) that are not then subject to outstanding “Awards” (as defined in the 2009 Plan). On June 20,
2019, at the Registrant’s 2019 Annual Meeting of Stockholders, the Registrant’s stockholders approved the 2019
Plan to succeed the Prior Plans. Upon stockholder approval of the 2019 Plan, no future awards will be made under the Prior
Plans.
In
addition, any shares subject to outstanding options or other equity “Awards” (as defined in the applicable
Plan) under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance
of the “Shares” (as defined in the applicable Plan), or if any such Award is settled for cash or otherwise does
not result in the issuance of all or a portion of the Shares subject to such Award (other than Shares tendered or withheld
in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the Shares to which those Awards were
subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be
available for delivery with respect to Awards under the 2019 Plan (such forfeited, expired or terminated shares under the
Prior Plans, the “Carryover Shares”).
Concurrently
with the filing of this Registration Statement, the Registrant is filing a post-effective amendment to its prior registration
statement on Form S-8 (File No. 333-191730), originally filed with the United States Securities and Exchange Commission (the “Commission”)
on October 15, 2013, to cover the issuance of (i) the Unused Plan Shares under the 2019 Plan and (ii) the Carryover Shares under
the 2019 Plan if and when they are available for issuance under the 2019 Plan.
PART
I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
The
documents containing the information specified in this Part I will be sent or given to participants of the 2019 Plan as specified
by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with
the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being
filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant
to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in the Registration Statement
pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a)
of the Securities Act.
PART
II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
|
|
Item
3.
|
Incorporation
of Documents by Reference.
|
The
Registrant hereby incorporates by reference into the Registration Statement the following documents previously filed with the
Commission:
(1)
The
Registrant’s Annual Report on
Form 10-K
for the year ended December 31, 2018, filed with the Commission on February 27,
2019;
(2)
The
Registrant’s Quarterly Report on
Form 10-Q
for the quarter ended March 31, 2019, filed with the Commission on May 8, 2019;
(3)
The
Registrant’s Current Reports on Form 8-K filed with the Commission on
April 17, 2019
,
April 25, 2019
,
June 7, 2019
and
June 21, 2019
(provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form
8-K shall not be incorporated by reference into this Registration Statement); and
(4)
The
description of the Registrant’s Common Stock included under the heading “Description of Common Stock” in the
prospectus forming a part of the Registration Statement on
Form S-3
(File No. 333-207837), as filed with the Commission on November
5, 2015, which description has been incorporated by reference in Item 1 of the Registrant’s
Form 8-A
(File No. 001-00100),
as filed with the Commission on October 6, 2017, including any amendment or report filed with the Commission for the purpose of
updating such description.
In
addition, all documents that the Registrant files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act
of 1934, as amended, subsequent to the effective date of this Registration Statement (except for any portions of the Registrant’s
Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed
with the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all
securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated
by reference in this Registration Statement and to be a part hereof from the date of filing such documents.
For
purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document
or statement in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Registration Statement.
|
|
Item
4.
|
Description
of Securities.
|
Not
applicable.
|
|
Item 5.
|
Interests of Named Experts and Counsel.
|
None.
|
|
Item 6.
|
Indemnification of Directors and Officers.
|
The
Registrant is a Nevada corporation and generally governed by the Nevada Private Corporations Code, Chapter 78 of the Nevada Revised
Statutes (“NRS”).
Section 78.138
of the NRS provides that, unless the corporation’s articles of incorporation provide otherwise, a director or officer is
not individually liable to the corporation or its stockholders or creditors for damages as a result of any action or omission
to act as a director or officer unless the trier of fact determines that the presumption that the director or officer acted in
good faith, on an informed basis and with a view to the interests of the corporation, is rebutted and it is proven that (i) the
director’s or officer’s acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such
breach involved intentional misconduct, fraud, or a knowing violation of the law.
Section 78.7502
of the NRS permits a Nevada corporation to indemnify its directors and officers against expenses, judgments, fines, and amounts
paid in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding,
if the officer or director (i) is not liable pursuant to Section 78.138 of the NRS, or (ii) acted in good faith
and in a manner the officer or director reasonably believed to be in or not opposed to the best interests of the corporation and,
if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. Section 78.7502
of the NRS precludes indemnification by the corporation if the officer or director has been adjudged by a court of competent jurisdiction,
after exhaustion of all appeals, to be liable to the corporation or for amounts paid in settlement to the corporation, unless
and only to the extent that the court determines that in view of all the circumstances, the person is fairly and reasonably entitled
to indemnity for such expenses and Section 78.7502 requires a corporation to indemnify its officers and directors if they have
been successful on the merits of the action or otherwise in defense of any claim, issue, or matter resulting from their service
as a director or officer.
Section
78.751 of the NRS permits a Nevada corporation to indemnify its officers and directors against expenses incurred by them in defending
a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof, upon determination
by the stockholders, the disinterested board members, or by independent legal counsel. Section 78.751 of the NRS provides
that the articles of incorporation, the bylaws or an agreement may require a corporation to advance expenses as incurred upon
receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court
of competent jurisdiction that such officer or director is not entitled to be indemnified by the corporation if so provided in
the corporation’s articles of incorporation, bylaws, or other agreement. Section 78.751 of the NRS further permits
the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation,
bylaws, or other agreement.
Section 78.752
of the NRS provides that a Nevada corporation may purchase and maintain insurance or make other financial arrangements on behalf
of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of
the corporation as a director, officer, employee, or agent of another company, partnership, joint venture, trust, or other enterprise,
for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee,
or agent, or arising out of his status as such, whether or not the corporation has the authority to indemnify him against such
liability and expenses. The Registrant has obtained primary and excess insurance policies insuring its directors and officers
and its subsidiaries against certain liabilities they may incur in their capacity as directors and officers. Under such policies,
the insurer, on the Registrant’s behalf, may also pay amounts for which the Registrant has granted indemnification to the
directors or officers.
The
foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference
to the above discussed sections of the Nevada Private Corporations Code.
The
Registrant’s amended and restated articles of incorporation, as amended, provide that the Registrant may indemnify to the
full extent of its power to do so, all directors, officers, employees, and/or agents. Insofar as indemnification by the Registrant
for liabilities arising under the Securities Act may be permitted to officers and directors of the Registrant pursuant to the
foregoing provisions or otherwise, the Registrant is aware that in the opinion of the Commission, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.
|
|
Item 7.
|
Exemption from Registration Claimed.
|
Not
applicable.
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
4.1
|
|
Composite
Amended and Restated Articles of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of
the Registrant’s Quarterly Report on Form 10-Q for quarter ended June 30, 2015, filed with the Commission on August
7, 2015).
|
|
4.2
|
|
Bylaws
of the Registrant (incorporated by reference to Exhibit C of the Registrant’s Definitive 14C Information Statement,
filed with the Commission on June 29, 2010).
|
|
4.3
|
|
First
Amendment to Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on
Form 8-K, filed with the Commission on December 22, 2015).
|
|
4.4
|
|
Form
of Certificate of Common Stock of the Company (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration
Statement on Form S-3, filed with the Commission on January 25, 2013).
|
|
5.1
|
|
Opinion
of DLA Piper LLP (US).
|
|
23.1
|
|
Consent
of Grant Thornton LLP, Independent Registered Public Accounting Firm.
|
|
23.2
|
|
Consent
of DLA Piper LLP (US) (contained in Exhibit 5.1).
|
|
24.1
|
|
Power
of Attorney (included on signature page).
|
|
99.1
|
|
TherapeuticsMD,
Inc. 2019 Stock Incentive Plan, and form of restricted stock unit agreement thereunder.
|
|
99.2
|
|
Form
of TherapeuticsMD, Inc. Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.2 to the
Registrant’s Current Report on Form 8-K, filed with the Commission on October 11, 2011).
|
(a)
The undersigned Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration Statement;
Provided,
however
, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.
(2)
That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial
bona fide
offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(b)
The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each
filing of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934
(and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial
bona fide
offering thereof.
(h)
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 21, 2019.
|
|
THERAPEUTICSMD,
INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Robert G. Finizio
|
|
|
Name:
|
Robert G. Finizio
|
|
|
Title:
|
Chief Executive Officer
|
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS
, that each person whose signature appears below hereby constitutes and appoints Robert G. Finizio
and Daniel A. Cartwright, and each one of them acting alone, as his true and lawful attorney-in-fact and agent, with full power
of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto
and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them acting alone, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying
and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully
do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
|
Name
|
Position
|
Date
|
|
/s/
Robert G. Finizio
|
Chief
Executive Officer, Director
|
June
21, 2019
|
|
Robert
G. Finizio
|
(Principal
Executive Officer)
|
|
|
/s/
John C.K. Milligan, IV
|
President,
Secretary, Director
|
June
21, 2019
|
|
John
C.K. Milligan, IV
|
|
|
|
/s/
Daniel A. Cartwright
|
Chief
Financial Officer, Treasurer (Principal Financial and Accounting Officer)
|
June
21, 2019
|
|
Daniel
A. Cartwright
/s/
Tommy G. Thompson
|
Chairman
of the Board of Directors
|
June
21, 2019
|
|
Tommy
G. Thompson
|
|
|
|
/s/
Jane F. Barlow
|
Director
|
June
21, 2019
|
|
Jane
F. Barlow
|
|
|
|
/s/
Brian Bernick
|
Director
|
June
21, 2019
|
|
Brian
Bernick
|
|
|
|
/s/
J. Martin Carroll
|
Director
|
June
21, 2019
|
|
J.
Martin Carroll
|
|
|
|
/s/
Cooper C. Collins
|
Director
|
June
21, 2019
|
|
Cooper
C. Collins
|
|
|
|
/s/
Robert V. LaPenta, Jr.
|
Director
|
June
21, 2019
|
|
Robert
V. LaPenta, Jr.
|
|
|
|
|
Director
|
June
21, 2019
|
|
Jules A. Musing
|
|
|
|
/s/
Angus C. Russell
|
Director
|
June
21, 2019
|
|
Angus
C. Russell
|
|
|
|
/s/
Nicholas Segal
|
Director
|
June
21, 2019
|
|
Nicholas
Segal
|
|
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
